Skip to main content

Idexx Laboratories guidance

  • IDXX · Nasdaq
  • Biotechnology
  • Health Care Equipment
  • S&P 500
$690.24−1.49%Close 17 Nov 2026 · Market value $54.38B

In its results release of 2 Nov 2026 (Q3 FY2026), Idexx Laboratories gave 4 forecasts in figures, among them revenue growth of +10.1% to +10.8% for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 2 Nov 2026

MeasurePeriodGuidanceAs stated
Revenue growth · RaisedFY2026+10.1% to +10.8%▪ Outlook for 2026 reported revenue growth raised to 10.1% - 10.8%, and CAG Diagnostics recurring revenue reported growth raised to 11.0% - 11.7%, with projected 2026 organic revenue growth of 9.3% - 10.0% and CAG Diagnostics recurring revenue organic growth of 10.3% - 11.0%.
Organic revenue growth · RaisedFY2026+9.3% to +10%The Company is increasing its outlook for organic revenue growth to 9.3% - 10.0%, an increase of 0.6% at midpoint, reflecting operational performance.
EPS · RaisedFY2026$14.96 to $15.16▪ Raises 2026 EPS outlook to $14.96 - $15.16, reflecting a $0.25 increase compared to prior guidance midpoint, led by a raised revenue outlook while supporting acquisition impacts.
Operating margin · LoweredFY202632.1% to 32.3%The Company lowered its full year reported operating margin outlook to 32.1% - 32.3%, bringing the projected full year operating profit margin expansion to 50 - 70 basis points as reported and on a comparable basis

Source: the company's earnings release.

Guidance against results above 1 · within 1 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
RevenueFY2026$4.63B to $4.72BGiven once—To come
Revenue growthFY2026+10.1% to +10.8%Raised once—To come
Organic revenue growthFY2026+9.3% to +10%Raised twice—To come
EPSFY2026$14.96 to $15.16Raised 3 times—To come
Operating marginFY202632.1% to 32.3%Raised once, lowered once—To come
Net incomeFY2026About $1.09BGiven once—To come
RevenueFY2025$4.05B to $4.17BGiven once$4.30BAbove the range
Revenue growthFY2025+9.6% to +10.3%Raised twice+10.42%Above the range
Operating marginFY202531.6% to 31.8%Raised twice31.6%Within the range

IDXX in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.